D
DBV Technologies SA D
D
DBVT
8.05000
USD
0.33
(4.27%)
قبل الجلسة
حجم التداول
824
الربح لكل سهم
-5
العائد الربحي
-
P/E
-2
حجم السوق
165,157,559
الأخبار المقالات
العنوان: DBV Technologies S.A
القطاع: Healthcare
الصناعة: Biotechnology
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.